Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) had its target price boosted by equities researchers at Jefferies Financial Group from $75.00 to $128.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective points to a potential upside […]
Jefferies Financial Group Increases Praxis Precision Medicines (NASDAQ:PRAX) Price Target to $128 00 themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at.
Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 564,000 shares, a growth of 15.9% from the January 15th total of 486,700 shares. Approximately 7.1% of the shares of the company are sold short. Based on an […]